

20 Dec 2016 |

Top Financing Of 2016: Cast Your Vote!

by Nancy Dvorin

It's time once again for **In Vivo's Deal of the Year** contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to [pick the winners](#). (It's free.)

In Vivo's Top Financing Of 2016 –The Nominees Are:

Another Big Round For Moderna: The \$474m equity financing that mRNA drug developer [Moderna Therapeutics LLC](#) raised in September will cover R&D, manufacturing and pipeline-expansion costs until it has proof-of-concept data in hand and can go public. [\[See Deal\]](#)

Grail Spins Out Of Illumina: In January, liquid biopsy play [Grail Bio](#) raised a \$100m-plus Series A round from top-flight investors, including majority owner [Illumina Inc.](#) In December, Grail announced it's on the hunt for another \$1.7bn to fund a clinical trial in half a million people. [\[See Deal\]](#)

Corporate Venture Bolsters Akili: Merck Ventures and Amgen Ventures participated in [Akili Interactive Labs Inc.](#)'s \$42m multi-tranche Series B round in 2016. The proceeds will fuel development of Akili's clinically-validated video game for assessing and treating cognitive disorders. [\[See Deal\]](#)

Samsung BioLogics' \$2bn IPO: The November initial public offering, the third largest in South Korea's history, is a big validation for biologics development in that country and also shows the importance of diversification for parent [Samsung Electronics Co. Ltd.](#)[\[See Deal\]](#)

DalCor Pharma Gets \$100 Million For CETP Inhibitor: Hoping for better luck than its big pharma counterparts have had with CETP inhibitors, [DalCor Pharmaceuticals](#) closed a \$100m Series B round to fund Phase III trials of dalcetrapib (licensed from [Roche](#), which terminated it for lack of efficacy) in a genetically distinct group of patients with acute coronary syndrome. [\[See Deal\]](#)

[CLICK HERE To Cast Your Vote For The Most Significant Financing Of 2016](#)

[CLICK HERE to Cast Your Vote For The Most Significant Strategic Alliance Of 2016](#)

Coming Up Next In IVDOTY16: Top M&A
